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Abstract: Objective: To evaluate trends in national emergency department (ED) adolescent opioid
use in relation to reported pain scores. Methods: A retrospective, cross-sectional analysis on National Hospital Ambulatory Medical Care Survey (NHAMCS) data was conducted on ED visits
involving patients aged 11–21 from 2008–2017. Crude observational counts were extrapolated to
weighted estimates matching total population counts. Multivariate models were used to evaluate
the role of a pain score in the reported use of opioids. Anchors for pain scores were 0 (no pain) and
10 (worst pain imaginable). Results: 31,355 observations were captured, which were extrapolated by
the NHAMCS to represent 162,515,943 visits nationwide. Overall, patients with a score of 10 were
1.35 times more likely to receive an opioid than patients scoring a 9, 41.7% (CI95 39.7–43.8%) and
31.0% (CI95 28.8–33.3%), respectively. Opioid use was significantly different between traditional pain
score cutoffs of mild (1–3) and moderate pain (4–6), where scores of 4 were 1.76 times more likely to
receive an opioid than scores of 3, 15.5% (CI95 13.7–17.3%) and 8.8% (CI95 7.1–10.6%), respectively.
Scores of 7 were 1.33 times more likely to receive opioids than scores of 6, 24.7% (CI95 23.0–26.3%) and
18.5% (CI95 16.9–20.0%), respectively. Fractures had the highest likelihood of receiving an opioid, as
49.2% of adolescents with a fracture received an opioid (CI95 46.4–51.9%). Within this subgroup, only
adolescents reporting a fracture pain score of 10 had significantly higher opioid use than adjacent
pain scores, where fracture patients scoring a 10 were 1.4 times more likely to use opioids than those
scoring 9, 82.2% (CI95 76.1–88.4%) and 59.8% (CI95 49.0–70.5%), respectively. Conclusions: While
some guidelines in the adult population have revised cut-offs and groupings of the traditional tiers on
a 0–10 point pain scale, the adolescent population may also require further examination to potentially
warrant a similar adjustment.
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1. Introduction
Acute pain is one of the primary reasons for visiting a US emergency department
(ED) [1] and over 20% of adolescents visit a US ED each year [2]. When treating moderate
to severe pain in this setting, healthcare providers may decide to use an opioid as treatment.
While some opioid guidelines exist [3–6], healthcare providers must constantly weigh in
the risks and benefits of using an opioid. These methods often rely on assessing factors
such as diagnosis, age, treatment goals, and pain severity before prescribing an opioid [7].
One factor of interest is the use of patient-reported pain scores to assess pain severity and
how that relates to the decision to prescribe an opioid.
Self-reported pain severity is a major factor used by clinicians to assess pain. Commonly used, these self-reporting tools are evidence of a patient’s experienced pain intensity [8]. However, the translation of these scores to treatment with analgesia are not
as closely correlated as one would expect There is often a high degree of interpatient
variability and reported pain can vary with factors such as age, sex, and ethnicity [9–11].
That said, current pain management guidelines unanimously agree that opioids should
be reserved for moderate to severe pain, but it is still unclear how pain scores are being
implemented in practice to guide key factors of prescribing opioids, such as duration of
treatment, follow-up, evaluation of dose escalation, and discontinuation [3,5,6].
The development of opioid misuse and abuse may stem from the introduction of an
opioid to individuals at an early age, which has prompted caution in providers caring for
adolescent populations [12,13]. Up to 40% of adolescent emergency department patients are
prescribed an opioid [14] and studies have shown variability in prescribing opioids within
this setting [15–18]. Earlier studies using the Center for Disease Control and Prevention’s
(CDC) National Hospital Ambulatory Medical Care Survey (NHAMCS) database have
found that pediatric patients who reported higher pain severity had a higher likelihood of
receiving an opioid analgesic over a non-narcotic analgesic [19,20]. In addition, pediatric
patients without a documented pain score were just as likely to receive an opioid when mild
pain was reported [20]. These studies used a four-tier pain severity scale: mild, moderate,
severe, and no pain.
To investigate how a pain score may interact with the provider’s assessment of a
patient, it is of interest to look at opioid prescribing rates in respect to a reported pain
score. Therefore, our primary objective is to evaluate patterns between pain scores and the
reported use of opioids to treat adolescents with pain within U.S. emergency departments.
Our secondary objective is to further explore the landscape of opioid use with pain scores
within subgroups such as diagnoses and age groups.
2. Methods
2.1. Study Design and Setting
This cross-sectional study analyzed data collected from the CDC’s NHAMCS. The
latest available years of NHAMCS data, representing visits from 2008 to 2017, was downloaded and coded by the investigators in May 2020. Statistical analysis was done in June
2020. NHAMCS is conducted nationally in the US using a representative sample of visits
to hospital-based outpatient clinics, emergency departments, and ambulatory surgery
locations in non-institutional and short-stay hospitals. Field representatives collected data
from medical records on patients’ symptoms, diagnoses, comorbidities, demographic characteristics, and medications ordered or provided. The survey employs a complex four-stage
study design, designed to represent all ED visits nationwide. Crude observation counts
were extrapolated to generate weighted estimates that matched the total population counts
provided by the Census Bureau. A detailed description of the data collection methodology can
be accessed at the CDC’s National Center for Health Statistics (NCHS) website [21]. The data
in this deidentified, publicly available database did not constitute as human subjects research
as defined by federal regulations and thereby exempted our study from IRB-approval.
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2.2. Patient and Public Involvement
As this study is a secondary analysis on a dataset that was collected and published by
the CDC, neither the patients nor the public were involved with providing input on the
study design, conduct, dissemination, nor evaluation to produce this manuscript.
2.3. Selection of Population
All emergency department visits involving patients aged 11–21 years were included
in the study and the study population was stratified into age groups of 11–14, 15–17, and
18–21 years old. This stratification was based on the American Academy of Pediatrics’
definitions of early, middle, and late adolescence [22].
Pain related visits were defined as visits with a documented pain diagnosis reported
in the reasons for visit, reported as International Classification of Diseases, Ninth Revision,
Clinical Modification codes. Pain diagnosis codes were established based on the clinical
classification software categories available from the Agency for Healthcare Research and
Quality Healthcare Cost and Utilization project. Visits that did not meet this criterion were
identified as non pain related visits.
2.4. Variables
The primary outcome was dichotomous opioid use in the ED, reported as used or
not used. Drugs were coded in terms of their generic component and therapeutic classification using Lexicon Plus® , North Kansas City, MO, USA, a comprehensive database of
medications available in the U.S. market. The classification of opioids or non-opioids was
determined using the CDC’s New Ambulatory Care Drug Database system [23].
Patient age, sex, race/ethnicity, insurance status (private, Medicaid, self-pay, other
payment method) were recorded at each visit. Information on whether the episode was an
initial visit or follow-up visit was also collected. Healthcare institution information was
also collected to determine region (Midwest, Northeast, South, West), and whether it was
in a metropolitan setting or not.
The NHAMCS uses a standard reason for visit classification to code complaints,
symptoms, or other reasons for visit. The summary of codes and diagnoses can be found in
the NHAMCS micro-data file documentation [24]. Included pain categories were abdominal
pain, fractures, injury excluding fractures, and musculoskeletal pain. Musculoskeletal pain
consisted of arthritis/joint pain, pelvic pain, back pain, and neck pain. Pain categories that did
not meet the minimum of 30 visits in the unweighted sample were categorized under other pain.
This group includes cancer-related pain, chest pain, cholelithiasis, headache, nephrolithiasis,
sickle cell anemia, dental or jaw pain, fibromyalgia, and peripheral neuropathy.
2.5. Pain Score Measurement
Self-reported pain scores were assessed at triage using a numerical rating scale of
0–10. Anchors for the maximum and minimum scores were (0) no pain and (10) worst
pain imaginable. Prior to 2008 the presenting level of pain was consolidated to no pain
(numerical rating of 0), mild pain (numerical rating of 1–3), moderate pain (numerical
rating of 4–6), and severe pain (numerical rating of 7–10) [24]. After 2008, stratified integer
pain scores from 0–10 were reported per case. In this study, unknown pain scores were
grouped together with scores of 0 due to the low counts of adolescent opioid patients and
were excluded in the logistic regression model.
2.6. Statistical Analysis
All analyses were conducted on weighted data, as recommended by the CDC’s NCHS
website. The weighting is calculated using the most recent census data to provide a stratified
representation of the national patient population. All participants’ records were stored in
a relational database using the open-source database software MySQL (v. 5.7.11, Oracle,
Redwood Shores, CA, USA). All analytics were performed using the open-source statistical
computing software R (v 3.2.3, R Foundation, Vienna, Austria). The functions of svydesign
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and svyglm from the R package survey were used to account for stratified, clustered, and
weighted variables in the NHAMCS data. Wald tests of association were used to determine
significance for bivariate analyses. Stepwise regression via backward elimination was
used including all independent variables mentioned above. Separate independent logistic
regression models were run holding pain score as the sole independent variable and opioid
use as the dependent variable. CDC detailed documentation of the NHAMCS instrument,
methodology and data files that were used as the basis for these analyses are available
elsewhere [25].
3. Results
3.1. Participants
The overall sample for analysis (n = 31,355) represented a weighted estimate of
162,515,943 ED visits by adolescent patients (aged 11–21 years old) within the 10-year study period, from 2008 to 2017. Among the patients who received a pain score, 56% (n = 92,550,318) of
the population was female and 44% (n = 69,965,625) were male. Approximately
53% (n = 89,125,196) were non-Hispanic White. Nearly half (n = 78,369,736) of the patients were late adolescents, aged 18–21, with 26% being (n = 41,730,020) mid-adolescents
aged 15–17 and 26% (n = 42,416,187) being early adolescents aged 11–14. Within this patient
population, there was a 31% reduction in opioid use between the two examined time
intervals of 2008–2012 and 2013–2017 (Table 1).
Table 1. Demographic Characteristics of a Weighted Sample of Adolescent Emergency Department
Visits in the US from 2008 to 2017 a .
Variable

Total Patients

Percent on Opioid (CI95)

Female
Male

92,550,318
69,965,625

16.8% (17.3–16.2%)
18.1% (18.8–17.5%)

Black
Hispanic
Other
White

39,255,551
29,956,070
4,179,126
89,125,196

14.1% (14.8–13.3%)
15.7% (16.6–14.7%)
18.3% (20.7–15.9%)
19.3% (19.9–18.7%)

11–14
15–17
18–21

42,416,187
41,730,020
78,369,736

11.3% (12.0–10.7%)
14.7% (15.5–13.9%)
22% (22.7–21.4%)

Metropolitan area
Non-metropolitan area
Unknown

120,279,731
24,884,524
17,351,688

17.9% (18.4–17.4%)
15.5% (16.6–14.4%)
16.5% (17.6–15.3%)

144,282,632
7,330,229
10,903,082

17.3% (17.7–16.8%)
20.9% (22.9–18.9%)
15.9% (17.4–14.4%)

73,585,030
88,930,913

20.9% (21.5–20.3%)
14.4% (15.0–13.8%)

109,946,374
8,829,988
43,739,581

18.9% (19.4–18.4%)
25.6% (27.5–23.8%)
11.8% (12.6–11.0%)

Sex

Race/Ethnicity

Age

MSA

Episode Of Care
Initial visit to this ED
Follow-up visit to this ED
Unknown/Missing Data
Time Interval
2008–2012
2013–2017
Prolonged Visit
Not Prolonged
Prolonged Visit
Unknown/Missing Data
a

Calculated using 95% confidence intervals; MSA, Metropolitan Statistical Area; ED, Emergency Department.
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43,739,581
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more opioids than other diagnoses with the same pain score. This second highest rate of
prescription was for patients diagnosed with musculoskeletal pain (Figure 2). In this part
of the analysis, pain scores of 0 and 1 within a diagnosis often did not meet the minimum
threshold for significance due to the low number of adolescent patients who received an
opioid at these scores.
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nephrolithiasis,
neuropathy. sickle cell anemia, dental or jaw pain, fibromyalgia, and peripheral neuropathy.

3.3.1. Fractures
3.3.1. Fractures
Pain related visits with fractures reported opioid use in 49% (CI95 46.4–51.9%) of
Pain related visits with fractures reported opioid use in 49% (CI95 46.4–51.9%) of vis‐
visits. The likelihood of receiving an opioid appears to be unaffected by pain scores
its. The likelihood of receiving an opioid appears to be unaffected by pain scores among
among patients who experienced a fracture and reported a pain score of 2–9, as none
of the scores reached statistical significance from one another. A patient with a score of
10 (82.2% (CI95 76.1–88.4%)) was 1.4 times more likely to receive an opioid prescription
than a patient with a score of 9 (59.8% (CI95 49.0–70.5%)).
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3.3.2. Musculoskeletal pain
In total, 34% (CI95 31.4–35.8%) of visits with musculoskeletal pain received an opioid.
Visits with musculoskeletal pain that reported mild and moderate pain scores of 2–6 did not
reach statistically significant differences among each other. Scores of 7 (43.3% (CI95 36.1–50.4%))
and higher were 2.6 times more likely to receive an opioid than scores of 5 (16.2%
(CI95 10.1–23.2%)) or lower.
3.3.3. Abdominal pain
Among visits with abdominal pain, 28% (CI95 25.7–29.3%) reported opioid use. For
patients who reported pain scores of 7 and above, opioid use rates were similar across all
severe pain scores and only when comparing to severe pain scores with mild or moderate
pain scores was there a significant change in opioids use rate, where a pain score of 10 was
1.7 times more likely to receive an opioid than a score of 6, 45.2% (CI95 38.8–51.5%) and
26.6% (CI95 20.8–32.3%), respectively.
3.4. Patient Age
To examine the utility of pain scores when accounting for patient age, ED visits were
subcategorized into three age groups (Figure 3). Within the late adolescent age group, the
rate of receiving an opioid has an uptrend with an increasing pain score. Statistical significance was seen from score of 3, 4, and 5, 12.5% (CI95 9.5–15.5%), 18.5% (CI95 15.6–21.4%),
and 24.4% (CI95 21.8–27.0%), respectively. A score of 10 (45.8% (CI95 43.2–48.4%)) was 1.2 times
more likely to receive an opioid than late adolescents scoring a 9 (37.9% (CI95 34.7–41.0%)).
Among the mid adolescent age group, the utility of the pain scores was less clear, with opioid use dropping at some of the higher reported pain scores. For instance, a pain score of 5
was 38% less likely to receive an opioid than a lower pain score of 4, 10.2% (CI95 7.8–12.7%)
and 16.7% (CI95 13.1–20.3%), respectively. A pain score of 9 was less likely to receive
an opioid than a pain score of 8, 20.1% (CI95 16.1–24.1%) and 27.2% (CI95 24.2–30.3%),
respectively. Within the early adolescent patient population, there was a notable increase in
opioid use at the moderate-severe pain score cutoff of 6 and 7, where early adolescent patients scoring a 7 (20.2% (CI9516.9–23.5%)) were 1.63 times more likely to receive an opioid
than patients with a score of 6 (12.4% (9.9–14.9%)). A score of 10 (30.6% (CI95 26.1–35.1%))
was not found to be statistically different from a score of 9 (23.4% (CI95 18.7–28.1%)) but
was 1.61 times more likely to receive an opioid than a score of 8 (19.0% (CI95 16.1–21.8%)).
No differences were seen within moderate scores ranging from 4–6, nor within mild scores
ranging from 1–3.
3.5. Patient Sex Differences
In male patients reporting a score of 4–10, representing moderate to severe pain, 57%
(CI95 55–58%) were given an opioid, whereas 49% (CI95 48–50%) of female patients with a
score of 4–10 were given an opioid. In severe pain scores of 8–10, higher proportions of
male patients received opioids than females (35% (CI95 34–37%) vs. 31% (CI95 30–32%)).
3.6. Multivariate Analyses: Logistic Regression
A logistic regression analysis followed by backwards stepwise elimination resulted
in a model of best fit that retained all loaded factors (Table 2). As expected, receiving
a pain diagnosis increased the odds of receiving an opioid, with fractures and musculoskeletal pain having the highest odds of receiving an opioid, 6.65 (CI95 5.29–8.36) and
2.57 (CI95 2.10–3.14), respectively. Pain scores were also shown to be statistically significant,
with patients being 1.25 times more likely to receive an opioid with each additional point
on a pain scale (CI95 1.22–1.28). Male patients were 19% more likely to receive an opioid
(OR 0.81 CI95 0.72–0.92). Age also contributed largely to the model, where older age groups
showed statistically significant odds ratios. Race and ethnicity did not reach statistical
significance in this model.
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Table 2. Logistic Regression Analysis of Predictors of Adolescent ED Opioid Use.
Odds Ratio (CI95)
(Intercept)

0.014 (0.009–0.023)

Ethnicity

Other
Black
Hispanic
White

0.775 (0.550–1.093)
0.992 (0.713–1.379)
1.241 (0.904–1.703)

Diagnosis

Non Pain Related
Abdominal Pain
Fractures
Injury excluding fracture
Musculoskeletal Pain
Other Pain Category

1.98 (1.650–2.375) *
6.653 (5.289–8.369) *
1.391 (1.211–1.598) *
2.573 (2.105–3.144) *
1.845 (1.498–2.271) *

Sex

Male
Female

0.811 (0.716–0.918)

Payment Method

Private Insurance
Medicaid, CHIP, State
Other Payment Method
Self-Pay

0.760 (0.668–0.865)
0.832 (0.685–1.01)
1.058 (0.895–1.25)

Adolescent Age

11–14
15–17
18–21

1.424 (1.203–1.687) *
2.399 (2.059–2.795) *

Prolonged ED visit

Not Prolonged
Prolonged
Missing Data

1.700 (1.405–2.057) *
0.647 (0.552–0.759)

Region

Northeast
Midwest
South
West

1.674 (1.353–2.072) *
2.076 (1.723–2.501) *
2.613 (2.089–3.267) *

Pain Scale

PAINSCALE

1.253 (1.224–1.283) *

Episode of Care

Initial visit to this ED
Follow-up visit to this ED
Unknown/Missing Data

1.408 (1.120–1.771) *
1.094 (0.807–1.485)

Metropolitan Area

Non Metropolitan Area
Metropolitan Area
Unknown

1.237 (1.003–1.526) *
0.936 (0.72–1.217)

* denotes significance using a 95% confidence interval.

4. Discussion
To our knowledge, our study is the first to utilize the 0–10 numeric rating scale data
in the NHAMCS dataset to examine opioid prescribing among adolescent emergency
department (ED) visits. Our data suggests that even with a 10 point scale, prescribers may
apply the traditional four-tier model for pain assessment, with the exception of a pain score
of 10, which is distinguished from the other pain scores from the “severe” tier. Reported
rates of opioid use versus independent pain scores showed a significant increase in opioid
use rates from 3 to 4 and 6 to 7, which is consistent with earlier NHAMCS studies that
examined pain intensity as mild, moderate, and severe pain. This trend may be due to
the general perception in clinical practice that these scores represent cutoffs between mild,
moderate, and severe pain. However, defining pain severity using a 0–10 pain scale has
been poorly studied. To our knowledge, the generally accepted current cutoffs, 0 (none);
1–3 (mild); 4–6 (moderate); and 7–10 (severe), were defined with the assumption that
it would be universally understood by both patient and provider [5]. Yet, studies have
demonstrated that there is a high degree of varying interpatient interpretability of pain
scales, resulting in different conclusions regarding the defined cutoffs for mild, moderate,
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and severe pain [26–28]. While a 10-point scale may provide more flexibility and insight on
the degree of pain a patient feels, the interpretation of the score should be used cautiously
and within a holistic context of the patient’s experience of pain.
Our results showed that there was a statistically significant difference in opioid prescribing for patients who scored a 10 compared to other “severe” scores, i.e., 7–9. This
was also observed within our subgroup analyses, where a score of 10 would regularly be
statistically different from other severe pain scores. These results challenge the interpretation that a score of 10 should be categorized in the same group as a score of 7–9. Likewise,
there were a few occurrences where statistically different opioid rates existed within the
moderate pain scores of 4–6. Though not statistically significant, there appeared to be a
higher likelihood of opioid use for a pain score of 1 than a score of 2 or 3. The trend could
be driven by other important factors such as diagnosis. Scores of 2 or 3 could consist more
so of visits associated with diagnoses that are better managed with non-narcotics. For
example, acute otitis media is better managed with an NSAID than an opioid. Although it
is unclear whether prescribers unintentionally utilize a different pain scale categorization
from the traditional 4-tier model, the data suggests that prescribers practice as though there
is a 5th tier that separates a score of 10, the worst pain imaginable, from other severe pain
scores. The way prescribers utilize lower tier pain scores to determine overall analgesic
use is not well defined in this study, as few patients used opioids for lower pain scores.
Adjustments to the categorization of these pain score ranges is a continual process; in recent
years, the NHAMCS revised their guidelines to redefine pain score interpretation, further
separating the scores into a six tier system; no pain (0–1), mild pain (2–3), discomforting
moderate pain (4–5), distressing-severe pain (6–7), intense-very severe pain (8–9), and unbearable pain (10) [29]. Even though the adoption of these pain score interpretations is yet
to be widespread with regard to documentation, our study would suggest that emergency
department providers already practice as if there was a different scale system in use.
The role of a pain score within the overarching umbrella of pain assessment is nuanced
and sometimes does not predict the delivery of analgesia. While it could be expected
that there is a general positive relationship between higher pain score and opioid use or
prescribing, studies have suggested that the correlation may sometimes be weak [30–32].
In one study examining emergency department visits of patients aged 3–20, there was
no statistical difference in analgesia administered nor time to administer the analgesia in
patients who reported a pain score of 6 or higher [31]. Our study had similar results when
opioid use rates were subcategorized by diagnosis. We found that within certain diagnoses,
opioid-use rates did not change over the span of pain scores that ranged from mild to
severe pain. Patients with fractures were more likely to receive opioids compared to other
diagnoses, but among patients with fractures, only patients scoring a 10 were more likely
to receive an opioid while scores ranging from 2–9 did not reach any statistical difference in
opioid rates. Rates with musculoskeletal pain increased between moderate pain and severe
pain, but there was no statistical difference once they reported a score of 7 or higher.
The output of the logistic regression model suggests that clinical factors that largely
contribute to the likelihood of receiving an opioid were diagnosis, sex, and age. Severe
conditions such as fractures and musculoskeletal pain had higher odds of receiving an
opioid. Sex-based differences were also observed in our subgroup analysis, showing that
males were likely to receive an opioid than females with similar pain scores. The underlying
cause of this disparity is indeterminate. However, differences in pain threshold between
genders, as well as provider perceptions on how genders report pain differently, may
be driving factors. The idea of age as a factor in pain management was supported with
our subgroup analysis, demonstrating an increase in opioid use among late adolescent
patients across pain scores. Treatment for the late adolescent group can be addressed using
some guidelines intended for the adult population, which may be a reason to why the
late adolescents had a steady trend with pain score. Meanwhile, the trend was less clear
with the younger age groups as there were statistically significant drops in opioid use
rates with some higher pain scores. The juxtaposition of different trends suggests that
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the reported pain scores of older patients may generally be viewed as more reliable than
younger patients’ reports, thereby suggesting that opioid prescription rates correlate with
pain scores better among older ages than younger ages. However, other considerations may
contribute to this trend, such as provider discomfort with opioid dosing in younger patients
due to a lack of guidelines with this vulnerable population and the potential increased risk
associated with opioid use in younger patients.
These findings were similar to other reports. Two other studies examining pediatric ED
opioid used identified age as a factor; both studies demonstrated decreased opioid use in
younger patients [33,34]. One study examining opioid use in North American EDs–Canada
and the United States demonstrated that more than 60% of providers regularly used codeinecontaining products for severe musculoskeletal pain in patients aged 15 years old, and more
than 30% used oxycodone-containing products for the same severe pain scenario [34]. The
rates of provider preference regarding opioid use is consistent with our finding that patients
reporting severe musculoskeletal pain are likely to receive opioid therapy. However, using
opioids for musculoskeletal pain in this population is a debated method and current
guidelines require additional research to improve the strategy [35].
Our results showed that certain pain scores within a range had similar opioid prescribing rates, suggesting that prescribers are less concerned with the precise score reported
and instead are more focused on categorizing the degree of severity of patient pain. The
traditional 4-tier model of defining pain severity–mild, moderate, severe, and no pain–does
not fit well with our results, as a score of 10 receives significantly more opioids than scores
of 7–9, which typically indicate severe pain. Future prospective studies are warranted to
identify how a traditional 4-tier model, the NHAMCS 6-tier model, and other models hold
up to analysis within a 0–10 point scale. Finding more accurate pain severity categories
may improve triage and screening practices and may be more accurate for reflecting the
actions that clinicians must intuitively perform with a 0–10 point scale score.
Additionally, defining pain score groupings may not only benefit prescribing decisions but also help highlight prescribing discrepancies. Our data showed that some patients
received opioids despite reporting mild pain, which is an opportunity for institutions to implement procedures of review to ensure appropriate opioid use. Likewise, a similar systematic
review process may be used for instances where patients reporting a score of 10 receive a
non-opioid analgesic instead of an opioid, ensuring that the decision is appropriate.
5. Limitations
The NHAMCS database only captures the presenting pain score, which therefore
limits the inference between pain score severity and opioid use. Information on the way in
which the opioid was used is also a limitation in this database, as it was unclear if opioids
were used empirically or for rescue therapy. The strength, frequency, dose, and timing of
opioid use are also missing. Opioids were evaluated as a homogenous group instead of
independent product of active ingredients due to the low cohort sizes. While information
on non-opioid analgesics is available within this dataset, it is unclear as to whether they
were used adjunctly or separately from the opioids. Other important considerations that
may be missed in our dataset include factors such as social history of drug misuse, location
of injury, presence of mood disorder, and allergies to either non-opioid or opioid analgesics.
In addition, other external factors may exist that influence provider decision making, such
as the type of hospital–academic versus community, pediatric versus adult—as well as,
health system protocols that provide guidelines for opioid use, as well as inter-provider
variability, where some providers may more or less be comfortable with utilizing narcotics
in this population. Furthermore, the pain score was collected at triage, and it is unclear
whether providers were required to know the patient’s pain score while making their
clinical assessment.
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6. Conclusions
Our examination of incremental pain scores suggests that, among the pain scores
associated with severe pain, a score of 10 significantly receives more opioids than the rest
of the severe pain scores of 7–9 reported from adolescents, whereas lower scores have
maintained consistent rates of opioid use within the respective groupings of mild and
moderate pain. While some guidelines have made this adjustment for the adult setting
and have separated a 10, the worst pain imaginable, from other severe pain scores, its
application to adolescent patients is yet to be fully understood. Furthermore, our subgroup
analysis suggested that the pain score relationship with opioid use was more nuanced and
that other clinical factors, such as diagnosis and patient age, affect the application of a pain
score for opioid use in the ED. Future research should examine additional factors that may
contribute to the prescriber decision-making process of using an opioid in this population
and setting.
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